155 related articles for article (PubMed ID: 9667275)
1. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors.
Orlefors H; Sundin A; Ahlström H; Bjurling P; Bergström M; Lilja A; Långström B; Oberg K; Eriksson B
J Clin Oncol; 1998 Jul; 16(7):2534-41. PubMed ID: 9667275
[TBL] [Abstract][Full Text] [Related]
2. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies.
Eriksson B; Bergström M; Orlefors H; Sundin A; Oberg K; Långström B
Q J Nucl Med; 2000 Mar; 44(1):68-76. PubMed ID: 10932603
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors.
Eriksson B; Bergström M; Lilja A; Ahlström H; Långström B; Oberg K
Acta Oncol; 1993; 32(2):189-96. PubMed ID: 7686763
[TBL] [Abstract][Full Text] [Related]
4. PET in the diagnosis of neuroendocrine tumors.
Sundin A; Eriksson B; Bergström M; Långström B; Oberg K; Orlefors H
Ann N Y Acad Sci; 2004 Apr; 1014():246-57. PubMed ID: 15153441
[TBL] [Abstract][Full Text] [Related]
5. The role of PET in localization of neuroendocrine and adrenocortical tumors.
Eriksson B; Bergström M; Sundin A; Juhlin C; Orlefors H; Oberg K; Långström B
Ann N Y Acad Sci; 2002 Sep; 970():159-69. PubMed ID: 12381551
[TBL] [Abstract][Full Text] [Related]
6. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.
Koopmans KP; Neels OC; Kema IP; Elsinga PH; Sluiter WJ; Vanghillewe K; Brouwers AH; Jager PL; de Vries EG
J Clin Oncol; 2008 Mar; 26(9):1489-95. PubMed ID: 18349401
[TBL] [Abstract][Full Text] [Related]
7. The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center.
Nikolaou A; Thomas D; Kampanellou C; Alexandraki K; Andersson LG; Sundin A; Kaltsas G
J Endocrinol Invest; 2010 Dec; 33(11):794-9. PubMed ID: 20332708
[TBL] [Abstract][Full Text] [Related]
8. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.
Orlefors H; Sundin A; Garske U; Juhlin C; Oberg K; Skogseid B; Langstrom B; Bergstrom M; Eriksson B
J Clin Endocrinol Metab; 2005 Jun; 90(6):3392-400. PubMed ID: 15755858
[TBL] [Abstract][Full Text] [Related]
9. Demonstration of high monoaminoxidase-A levels in neuroendocrine gastroenteropancreatic tumors in vitro and in vivo-tumor visualization using positron emission tomography with 11C-harmine.
Orlefors H; Sundin A; Fasth KJ; Oberg K; Långström B; Eriksson B; Bergström M
Nucl Med Biol; 2003 Aug; 30(6):669-79. PubMed ID: 12900293
[TBL] [Abstract][Full Text] [Related]
10. Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography.
Sundin A; Eriksson B; Bergström M; Bjurling P; Lindner KJ; Oberg K; Långström B
Nucl Med Biol; 2000 Jan; 27(1):33-41. PubMed ID: 10755643
[TBL] [Abstract][Full Text] [Related]
11. 11C-5-hydroxytryptophan positron emission tomography after radiofrequency ablation of neuroendocrine tumor liver metastases.
Norlén O; Nilsson A; Krause J; Stålberg P; Hellman P; Sundin A
Nucl Med Biol; 2012 Aug; 39(6):883-90. PubMed ID: 22381780
[TBL] [Abstract][Full Text] [Related]
12. Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors.
Carlbom L; Caballero-Corbalán J; Granberg D; Sörensen J; Eriksson B; Ahlström H
Ups J Med Sci; 2017 Mar; 122(1):43-50. PubMed ID: 27894208
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic neuroendocrine tumors: diagnosis with PET.
Ahlström H; Eriksson B; Bergström M; Bjurling P; Långström B; Oberg K
Radiology; 1995 May; 195(2):333-7. PubMed ID: 7724749
[TBL] [Abstract][Full Text] [Related]
14. Positron-emission tomography as a radiological technique in neuroendocrine gastrointestinal tumors.
Eriksson B; Lilja A; Ahlström H; Bjurling P; Bergström M; Lindner KJ; Långström B; Oberg K
Ann N Y Acad Sci; 1994 Sep; 733():446-52. PubMed ID: 7978893
[No Abstract] [Full Text] [Related]
15. Other PET tracers for neuroendocrine tumors.
Koopmans KP; Glaudemans AW
PET Clin; 2014 Jan; 9(1):57-62. PubMed ID: 25029934
[TBL] [Abstract][Full Text] [Related]
16. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography.
Orlefors H; Sundin A; Lu L; Oberg K; Långström B; Eriksson B; Bergström M
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):60-5. PubMed ID: 16184369
[TBL] [Abstract][Full Text] [Related]
17. Nuclear medicine imaging of neuroendocrine tumours.
Bombardieri E; Maccauro M; De Deckere E; Savelli G; Chiti A
Ann Oncol; 2001; 12 Suppl 2():S51-61. PubMed ID: 11762353
[TBL] [Abstract][Full Text] [Related]
18. Kinetic compartment modeling of [11C]-5-hydroxy-L-tryptophan for positron emission tomography assessment of serotonin synthesis in human brain.
Hagberg GE; Torstenson R; Marteinsdottir I; Fredrikson M; Långström B; Blomqvist G
J Cereb Blood Flow Metab; 2002 Nov; 22(11):1352-66. PubMed ID: 12439293
[TBL] [Abstract][Full Text] [Related]
19. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Kema IP; Koopmans KP; Valk GD; Timmers HJ; de Herder WW; Feelders RA; Fockens P; Sluiter WJ; de Vries EG; Links TP
Gastrointest Endosc; 2015 Jan; 81(1):159-167.e2. PubMed ID: 25527055
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography (PET) with 11C-5-hydroxytryptophan (5-HTP) in patients with metastatic hormone-refractory prostatic adenocarcinoma.
Kälkner KM; Ginman C; Nilsson S; Bergström M; Antoni G; Ahlström H; Långström B; Westlin JE
Nucl Med Biol; 1997 May; 24(4):319-25. PubMed ID: 9257330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
